CANreduce 2.0 - comparing two differently optimized versions of a web-based self-help program to reduce cannabis use with each other and a waiting list

Conditions

Problematic cannabis use Mental and Behavioural Disorders

Joachim Ahlers, Christian Baumgartner, Mareike Augsburger, Andreas Wenger, Doris Malischnig et al. (11 authors)

Journal of Medical Internet Research2022-02-0927 citations

CANreduce 2.0 Adherence-Focused Guidance for Internet Self-Help Among Cannabis Users: Three-Arm Randomized Controlled Trial

Christian Baumgartner, Michael P Schaub, Andreas Wenger, Doris Malischnig, Mareike Augsburger et al. (11 authors)

Journal of Medical Internet Research2021-04-0322 citations

10.2196/27463

The Effects of Social Presence on Adherence-Focused Guidance in Problematic Cannabis Users: Protocol for the CANreduce 2.0 Randomized Controlled Trial

Manuel Amann, Severin Haug, Andreas Wenger, Christian F. Baumgartner, David Daniel Ebert et al. (9 authors)

JMIR Research Protocols2018-01-3120 citations

10.2196/resprot.9484

Interventions

Participants are randomly allocated to one of three arms: 1. Intervention group: Adherence-focused guidance enhanced web-based self-help program 2. Active control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cannabis use of at least once a week 30 days prior to study entry 2. At least 18 years old 3. At least weekly internet access and a valid email address

Exclusion criteria

Exclusion criteria: 1. Current pharmacological psychiatric disease or history of psychosis, schizophrenia, bipolar type I disorder or significant current suicidal or homicidal thoughts 2. Use of other pharmacological and psycho-social treatments for cannabis use disorders 3. Inability to read or write in German

Design outcomes

Primary

Measure	Time frame
Quantity and the number of days per week of cannabis use. Participants enter their cannabis consumption quantity and frequency into their consumption diary every week. Timepoints of measures will be initial assessment, after 6 weeks and at 3 months follow-up.	—

Secondary

Measure	Time frame
1. Severity of cannabis dependence (SDS) 2. The use of alcohol, tobacco, and other non-cannabis illicit drugs (FDA) 3. Changes in depression, anxiety and attention deficit symptoms (CES-D, GAD-7 and ASRS-V1.1) 4. Post traumatic Stress Disorder (Short Screening Scale for DSM-IV) 5. Client satisfaction (ZUF-8) Severity of cannabis dependence and the use of alcohol, tobacco, and other non-cannabis illicit drugs will be measured at initial assessment, after 6 weeks and at 3 months follow-up. Changes in depression, anxiety, attention deficit symptoms and the Short Screening Scale for DSM-IV Post traumatic Stress Disorder will be measured at initial assessment and at 3 months follow-up. Client satisfaction will be measured after 6 weeks.	—

Measure

Time frame

1. Severity of cannabis dependence (SDS) 2. The use of alcohol, tobacco, and other non-cannabis illicit drugs (FDA) 3. Changes in depression, anxiety and attention deficit symptoms (CES-D, GAD-7 and ASRS-V1.1) 4. Post traumatic Stress Disorder (Short Screening Scale for DSM-IV) 5. Client satisfaction (ZUF-8) Severity of cannabis dependence and the use of alcohol, tobacco, and other non-cannabis illicit drugs will be measured at initial assessment, after 6 weeks and at 3 months follow-up. Changes in depression, anxiety, attention deficit symptoms and the Short Screening Scale for DSM-IV Post traumatic Stress Disorder will be measured at initial assessment and at 3 months follow-up. Client satisfaction will be measured after 6 weeks.

—

Countries

Austria, Germany, Switzerland

Contacts

Public ContactManuel Amann

Outcome results

None listed